Ianalumab in Sjögren's syndrome: what can we learn from lupus trials? - Authors' reply.

Saved in:
Bibliographic Details
Title: Ianalumab in Sjögren's syndrome: what can we learn from lupus trials? - Authors' reply.
Authors: Bowman SJ; Rheumatology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2TH, UK; Institute of Inflammation and Ageing, College of Medical and Dental Sciences and National Institute for Health Research Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK; Rheumatology Department, Milton Keynes University Hospital, Milton Keynes, UK. Electronic address: simon.bowman@uhb.nhs.uk., Dorner T; Department of Medicine, Rheumatology and Clinical Immunology, Charité Universitätsmedizin and Deutsches Rheumaforschungszentrum, Berlin, Germany., Mariette X; Université Paris Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, INSERM U1184, Le Kremlin Bicêtre, France., Luo WL; Novartis Pharmaceuticals, East Hanover, NJ, USA., Hueber W; Novartis Pharma, Basel, Switzerland.
Source: Lancet (London, England) [Lancet] 2022 Sep 10; Vol. 400 (10355), pp. 808-809.
Publication Type: Letter; Comment
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-547X
DOI:10.1016/S0140-6736(22)01538-0